MedTech Actuator Origin is back – apply today!

Are you an aspiring entrepreneur with a MedTech, BioTech or HealthTech startup idea? Apply now for the 2021 MedTech Actuator Origin!

All superheroes have a beginning and so do startup founders. Transform your idea or research with MedTech Actuator Origin – a two month early-stage entrepreneurship competition that will help you translate your concept into an impact orientated health venture.

Whether you’re a researcher, scientist, clinician, student or garage inventor, MedTech Actuator Origin is looking for passionate entrepreneurs to transform healthcare. Apply today!

The MedTech Actuator Origin experience

Delivered in-person and online, MedTech Actuator Origin is open to Australian health entrepreneurs and will run from October to December 2021. Our experts will pressure test your idea and expose you to the world of startups through:

  • Workshops – gain insight into what it takes to protect your idea and learn how to craft a prize-winning pitch.
  • Rapid Fire Round – pitch your concept to a panel of industry leaders and peers, putting your idea and pitching skills to the test.
  • Mentoring – receive tailored mentorship from industry experts who will help you bring your MedTech, BioTech or HealthTech innovation to market.
  • Access to the MedTech Actuator knowledge hub – commercialisation 101 curated content for researchers and medical professionals turned entrepreneurs.
  • Sprint Intensive – access a 3-day sprint intensive where you’ll dive into the world of entrepreneurship and commercialisation, including workshops, founder stories, panel discussions, activities, and heaps more!
  • Pitch Competition – bring together all your ideas in a short, 3-minute pitch to a select panel of judges to earn one of three places at the MedTech Actuator Showcase, a $15k cash prize and over $5k worth of in-kind prizes.
  • MedTech Actuator Showcase – pitch your idea to the ecosystem at the MedTech Actuator Showcase, a black-tie gala event for investors, industry-leaders, corporate partners and global MedTech companies.

The Origin winner will take home $15k in cash and have the opportunity to be fast-tracked through the application process for the MedTech Actuator – Asia Pacific’s MedTech accelerator – moving your product even closer to market.

Meet Amy Yu – MedTech Actuator Origin alumna

Photo of Amy Yu in MedTech Actuator superhero tee, Melbourne lane way by night.
Amy Yu, MedTech Actuator Origin alumna & Ventora Medical CTO.

“Ventora Medical spun out of the BioDesign Innovation program at the University of Melbourne. As soon as we graduated in 2018, we entered MedTech Actuator Origin. For Ventora, MedTech Actuator Origin really was the first point of validation from the MedTech entrepreneurial community in Melbourne. We were lucky enough to get through each round and be selected as a top five finalist.

You don’t know what you don’t know, and MedTech Actuator Origin taught us just that. At the bootcamps we took that all in, like sponges, and learnt so much from MedTech Actuator. This was backed up by networking with people who helped us achieve all of those unknowns and hit milestones.”

– Amy Yu, MedTech Actuator Origin alumna and Ventora Medical CTO, Forbes 30 Under 30

Key dates

  • Applications open: 6 Aug – 30 Sep
  • Finalists announced: 1 Oct
  • Online MedTech Actuator Origin Workshops: 7 Oct
  • Rapid Fire Round Pitch: 21 Oct
  • Mentoring and Sprint Intensive preparation: 22 Oct – 15 Nov
  • Sprint Intensive: 15 Nov – 17 Nov
  • Semi-finals Pitch: 17 Nov
  • MedTech Actuator Showcase and Finals Pitch: 9 Dec

Apply now

Are you ready to transform your idea and build your origin story – or do you know someone who is? Find out more about MedTech Actuator Origin and apply today.

NanoMSlide manufacturing smart microscope slides in Melbourne.

A new facility at the Australian National Fabrication Facility has made it possible for MedTech Actuator startup NanoMSlide to manufacture their smart nanotechnology microscope slides onshore for instant, more accurate cancer diagnosis.

Until now NanoMSlide has relied on overseas facilities for production of their invention. Housed at the Melbourne Centre for Nanofabrication Facility the new half-a-million dollar Phabler facility will enable industry, academia, and companies such as NanoMSlide to scale up production of nanoscale devices.

“With the Phabler facility we are now able to manufacture our slides right here in Melbourne and in quantities that will allow us to realise the full potential of our invention,” says NanoMSlide founder Professor Brian Abbey.

Current diagnostics of cancer in cells and tissues rely on chemicals, dyes, and extensive pre-processing of samples – taking valuable time and making accurate diagnosis more challenging. The new Phabler facility will make it possible for NanoMSlide to apply their patented nanopatterned coating to a conventional microscope slide, and create high-contrast images that instantly show the difference between cancerous and healthy cells.

NanoMSlide joined the MedTech Actuator in 2019 to develop their business model, connect with local and international partners and investors, build skills required to form a successful startup, and test their value proposition. The 15-month, industry-led, venture-backed program aggressively funds and accelerates medical, health and biological technology startups.

“One of the biggest challenges I faced in the MedTech Actuator was moving outside my comfort zone as a researcher,” says Brian. “As a startup founder you need to fulfil many roles and at the beginning I found pitching particularly hard. But as the program progressed I gained in confidence and experience.”

Brian is driven by the desire to improve outcomes for patients and to reduce the rate of misdiagnosis. Their invention is initially being used to diagnose early-stage breast cancer – and the team intend to scale for instant, more accurate diagnosis of other forms of cancer.

“As we are working on critical, life-changing problems, we constantly strive to develop our technology and deliver the best possible product,” says Brian.

The Medtech Actuator has connected the company with potential investors and industry partners. This dense innovation ecosystem is critical to success – Brian says it is important for MedTech entrepreneurs to seek advice from diverse experts and to be prepared to challenge your assumptions.

“We realised a few times in the MedTech Actuator that our initial plan was not ideal from a commercial perspective. While it was a difficult decision to change direction, the company is now in a much stronger position,” says Brian.

“I would recommend the MedTech Actuator to anyone with a great idea or potential product in the MedTech space – the community and support are fantastic and we had an unforgettable experience.”

Learn more about how the new Phabler tool is supporting NanoMSlide to manufacture their invention onshore and scale in this story from the Australian National Fabrication Facility.

La Trobe University aims to engage with industry partners and commercialise the NanoMSlide through a new spin-out company, AlleSense. Find out more.

Safeguarding frontline & essential workers from COVID-19 & future pandemics.

Expression of interest recently opened to invest in Soterius. The MedTech Actuator startup is scaling its COVID-19 biosensor to help protect workers and the wider community from devastating health, social and economic impacts of future pandemics.

The reliable, accurate and non-invasive Soterius biosensor delivers immediate results, informing whether an individual is required to test for infection and self-isolate or providing the all-clear to enter their work environment. The biosensor will initially be delivered to hospitals, with future applications in other frontline and essential worker settings including quarantine hotels, airports, and schools.

Emerging environmental viral sensors are bulky, energy intensive and specific to one virus. In contrast, the Soterius biosensor is so small that it fits on a personal fob card and is now scaling to detect other respiratory illnesses. Importantly, the biosensor is easy to use: individuals just swipe their card over a reader at checkpoints.

Prototype tests revealed that the biosensor detects SARS-CoV-2 spike protein in the picomolar range with impressive accuracy and reliability. SARS-CoV-2 is the virus responsible for COVID-19. This indicates that Soterius could be a top performing diagnostic for respiratory illnesses by immediately detecting the lowest presence of viral load.

Founded by Dr Alasdair Wood and Dr Chih Wei Teng, the Soterius biosensor is being developed in collaboration with the Burnet Institute, RMIT University, D+I and Vestech.

“In 2019, when the terms ‘social distancing’ and ‘stage 4 lockdown restrictions’ were unheard of, we observed inherent weaknesses in the world’s ability to protect itself against respiratory infection,” recalls Alasdair.

Alasdair and Chih Wei joined the MedTech Actuator – Asia Pacific’s MedTech catalyst – in 2019 to validate their ideas, connect with product designers and partners, and build the skills necessary for scaling their company.

“The MedTech Actuator is a complete package. You’re bound to learn and gain new perspectives, no matter how experienced you are,” says Chih Wei.

For Alasdair, the camaraderie and friendship amongst startups has also been a highlight.

“Peer learning is always great – we went through highs and lows together in a safe environment. I also love the people that populate the MedTech Actuator. The team is great and the people they bring in are amazing – including mentor Dr Elane Zelcer. Our new connections with peers, mentors and the wider ecosystem persist beyond the program,” says Alasdair.

“The MedTech Actuator provides the tools and connections to make ideas a reality, which is a very exciting proposition. But be ready to sprint!”

Reach out to Co-Founder and CEO Chih Wei Teng at chih(@)soterius.com.au to express interest in becoming a Soterius investor.

See the Soterius biosensor in this recent Channel 9 News story and read more about the technology and collaboration in this RMIT University media release.

Photo courtesy of RMIT University: Soterius sensors being prepared at RMIT University’s Micro Nano Research Facility for advanced manufacturing of cutting-edge electronics.

Asia Pacific’s best emerging health entrepreneurs join MedTech Actuator.

Entrepreneurs working to improve and save lives through health innovation have joined the MedTech Actuator – Asia Pacific’s MedTech catalyst.

We wish a warm welcome to our new cohort of clinicians, researchers and other changemakers with big plans to radically accelerate their medical, health or biological technology prototype or proof-of-concept:

  • GenEmbryomics: IVF Embryo Whole Genome Sequencing.
  • Gild: Improving healthcare access by developing gap-payment technology.
  • HatiSens: A handheld sensing device that can accurately diagnose heart attack in under 10 minutes.
  • Moon technologies: Providing emergency patients’ health data to paramedics in real-time.
  • Osteo-X: An internally self-locking intramedullary nail (orthopaedics) that reduces surgical time and radiation exposure.
  • Quitta: Developing safe, effective nicotine replacement therapies for the world’s 1.3 billion smokers.
  • The Mindful Mum (Rebranding to “Nourri”): A digital health platform that helps modern families nurture their health and happiness – for everyone’s benefit.
  • Virtetic: Empowering the prosthetics community through virtual reality.
  • XLR8: Developing wearable sensors and Rebee application to allow patients to perform physical rehabilitation exercises anywhere, any time.
  • Yabi: An innovative, accurate and automated method for monitoring and escalating surgical drain output.

The MedTech Actuator’s specialised acceleration model will surround the startups with the ecosystem support they need to bring their MedTech, HealthTech or BioTech innovation to the patients and clinicians who need it most.

Through MedTech Actuator’s intensive mentorship, industry collaboration, up to AUD$200K initial capital injection and capital raising support, the founders can achieve in 15 months what can typically take 3 years or more.

Embedded in the MedTech Actuator™ ecosystem, they will radically advance their technology development, raise seed capital, and build critical business and management skills. They will become primed and ready to grow their venture even further – including raising series A funding, commencing clinical trials, gaining regulatory approvals, and moving to at-scale manufacturing, and market launch.

Integrated across Asia Pacific, the industry-led MedTech Actuator will open an unrivalled network to founders, including 85 partners and 75 mentors from some of the largest names in health innovation spanning multi-national corporations, hospitals and clinicians, investor groups and VCs, professional service partners, universities and research institutions, and product development firms.

They will go on to join an alumni network of the brightest emerging startups from across Asia Pacific and our networks are their networks as they scale up, prepare for exit and beyond.

To follow founders and their journey sign up to our newsletter below and connect with us on LinkedIn and Twitter.

AI technology reducing discomfort for patients during childbirth.

A traumatic childbirth drives MedTech Actuator alumna, Cailin Ng – CEO and Co-Founder of Singapore-based HiCura Medical – to advance an AI-powered technology that can significantly reduce discomfort and risks for women around the world.

During caesarean birth and vaginal birth women often endure painful repeated needles for spinal anaesthesia, and risk complications such as nerve injury – and in rare cases, paralysis.

HiCura’s artificial intelligence-powered imaging assistant, uSINE reduces pain and risks by delivering spinal anaesthesia in the right location, at the right angle, the first time. One study revealed that doctors were able to achieve a first attempt success rate of 92 per cent using uSINE, far higher than the global first attempt success rate of 50 to 60 per cent.

“Women all over the world choose epidural to relieve their pain during childbirth. I truly hope my technology will help them, so they do not have the traumatic experience I had,” says Cailin.

HiCura joined MedTech Actuator – Asia Pacific’s MedTech, HealthTech and BioTech accelerator in 2020 to connect with Australian hospitals and investor networks. 

“As a startup in Singapore, the MedTech Actuator is helping us to establish important connections in Australia’s MedTech network,” says Cailin.

“We identified Australia as a potential market to expand into, as we saw that the adoption of MedTech innovation in Australia’s hospitals and investor sentiment is very positive. I would definitely recommend MedTech Actuator to other Singapore MedTech startups.”

HiCura’s biggest challenge was commercialisation.

“The MedTech industry is complex with many stakeholders. You have to consider the hospital, doctors, patients, insurance companies, and regulatory compliance,” says Cailin. 

“Unlike any consumer or industrial product where you can ‘test’ the market by selling and revising the product, the route to commercialisation for a MedTech device is a long and arduous one involving clinical trials and regulatory approval.”

The MedTech Actuator supported HiCura through this challenge, and the company has now validated the product and developed a regulatory strategy.

The HiCura team found the experience of being surrounded by a community of MedTech startups on the same journey very valuable.

“Having friends around to listen is very helpful as the world of MedTech startups can be stressful. We could share our joys and frequent challenges,” says Cailin.


Making it possible for seniors to live better longer.

MedTech Actuator alumnus Gabriel is developing technology that delivers more proactive and integrated care to the elderly at home, hospitals and aged care facilities by helping family, clinicians and carers to be in the right place, at the right time, with the right support.

“We founded our family business together as Dad is getting older, and didn’t want to be a burden on us as he ages,” says Gabriel Co-Founder and Chief Marketing Officer, Maria Crews.

Maria, her brother, and father looked around the world and found that there was no complete, reliable system that would provide the level of care and protection that they wanted for their father, and that he wanted for himself.

“So we set out to create the ultimate solution,” says Maria. Gabriel helps to prevent serious complications experienced by the elderly including falls, bedsores and eloping from buildings.

In one trial, Gabriel found that an aged care resident had spent two hours alone on the bathroom floor after a fall and eventually managed to return to bed.

“When we spoke to the site, they had no record of that fall having occurred – but now we can provide real-time tools to understand and respond with the care that is required.”

Maria recognises that people can be hesitant to ask for help and that the elderly are no exception, fearing that it may lead to life in an aged care home.

“That’s why everything that we do is not only proactive, it’s also passive. The person doesn’t have to do anything, nor do their family, clinicians and carers – we do it all for them. And we’re doing it in a way that protects and preserves their dignity.”

This inspired the name, Gabriel. “It’s like having a guardian angel looking out for you. The system keeps an eye on you or your loved one, patient or resident, and looks after everything for you.”

Maria’s MedTech Actuator experience and networks are helping to bring Gabriel’s technology to people around the world faster.

“The MedTech Actuator built our understanding of navigating the MedTech landscape – from regulatory environments, to rules of engagement, networks, key players and the right people to talk to,” says Maria.


RehabSwift advancing a customised brain-computer interface for stroke recovery.

MedTech Actuator startup RehabSwift Pty Ltd is developing a personalised brain-computer interface that revives hand movement after stroke, a leading cause of long-term disability worldwide.

Leveraging the brain’s neuroplasticity, RehabSwift rewires damaged neural pathways between the brain and muscles. The technology records the electrical activity of the patient’s brain through their scalp, detects their intention to move using a novel machine learning algorithm, then transforms this captured intention into the actual movement via robotic hands.

Founder and Managing Director, Dr Sam Darvishi is driven to make a difference to people living with disability.

“I stuttered severely through my childhood and teenage years,” says Sam. “As someone who has lived with disability, I know how hard it is. I’ve always intended to use my knowledge and expertise to ease the burden of disability.”

Sam is well on his way to achieving this. In a proof of principle study, RehabSwift improved the hand motor function of a stroke survivor, who had a stroke 3.5 years prior to the study, by 36% after ten 30-minute therapy sessions.

Sam joined the MedTech Actuator in 2018 to access education and mentorship in developing RehabSwift’s commercialisation strategy. The MedTech Actuator is Asia Pacific’s MedTech, HealthTech and BioTech catalyst, supported by the REDI initiative and powered by MTPConnect.

“Thanks to the MedTech Actuator’s wealth of knowledge and expertise, we were able to establish strategy around clinical trials, product development, regulations, reimbursement, marketing, IP, finance, and go-to-market,” says Sam.

“MedTech startups are different to startups in other industries, as they need to survive with no revenue for at least few years until they reach the market. The MedTech Actuator gave us education and mentorship tailor-made for medical devices – general advice would not have been particularly useful,” says Sam.

In 2020 RehabSwift was awarded an Accelerating Commercialisation Grant of $144,590, supporting Sam to make the innovative device available to stroke survivors.

RehabSwift also received ethics approvals in 2020, and work is ongoing in product development and testing, patient screening and recruitment for clinical trials, and conducting clinical trials to continue refining the device.

“My advice for those on similar pathways is to find your why,” says Sam.

“Knowing why you do what you do can make it much easier to bear inevitable hardship. Otherwise the setbacks may be too tough to withstand.”

To learn more about RehabSwift and follow their journey, go to www.rehabswift.com.

Applications are now open for MedTech Actuator 2021. If you’re ready to radically accelerate your innovation to improve and save lives, find out more and apply.

Apply now

Pronto Bottle raises $175K crowdfunding on Birchal in midst of COVID19.

Form-i-Baby has reached their crowdfunding target on Birchal in the midst of the COVID19 global pandemic, raising AUD$175K and welcoming 140 new investors to advance Pronto Bottle – a world-first self-sterilising baby bottle.

The technology will make bottle feeding safer for babies, save precious time for parents and keep millions of bottles out of landfill every year.

The impressive raise will allow Pronto Bottle to finalise a new and improved prototype and proceed to lab testing, and testing with parents and key opinion leaders. Behind the scenes, the Melbourne-based startup is now raising a larger round of $675K to support subsequent tooling, manufacture, and launch.

Founded by award-winning entrepreneur Shannon Gilleland, the bottle was recently compared to Apple with Alex Zaharov-Reutt from iTWire saying, “If Apple had a baby, Pronto would be it.”

The durable bottle uses the latest ultraviolet light wave technology to self-sterilise at home and on the go, freeing up around an hour every day on bottle preparation and reducing the bottles a family needs down to just one.

Form-i-Baby have invested heavily in market research, prototyping, and testing since the concept was first born. The company has been working on building relationships with manufacturers, distributors, sales, and marketing agents, with discussions now in progress for joint venture opportunities across Australia and Asia.

Shannon joined Asia Pacific’s MedTech, BioTech and HealthTech accelerator, MedTech Actuator in 2019 to gain personal mentoring and technical knowledge on the MedTech industry. Through MedTech Actuator, Shannon gained expertise in manufacturing, marketing, strategy, IP, commercialisation, and leveraged support on fundraising and investor relationships.

Shannon says that the bespoke industry masterclasses, and personal mentorship throughout and after the program have supported her startup journey.

“The intense masterclasses from professionals who have worked in MedTech, BioTech and HealthTech industries, and this unique skill set, would be very difficult to source elsewhere,” says Shannon.

“The close mentorship provides honest feedback on your direction, skills, progress, expertise and weaknesses, ensuring you never get to walk around with your ‘startup blinkers’ on.”

“The immense network of industry contacts that you can tap into is something you wouldn’t be able to access unless you were in the industry yourself for 20+ years, and even then, it wouldn’t be as diverse.”

Applications are now open for MedTech Actuator 2021. If you’re ready to radically accelerate your innovation to improve and save lives, find out more and apply.

Apply now

Next generation tissue building & regenerative medicine for neural repair.

Inaugural MedTech Actuator Menzies Fellow Associate Professor Jeremy Crook is developing a world-first neural repair medical technology to improve the lives of people living with neural tissue damage as a result of illness or trauma.

Neurons or nerve cells are key players in our brains and nervous system. Everything that we think, feel, and do requires the work of neurons and their support cells. Our complex neural networks make it possible for information to flow between different areas of our brain, spinal cord and connect to the rest of our body. Without them, we could not receive sensory information from the world around us or control our muscles and organs.

When nerve cells are damaged, whether as a result of trauma, stroke, tumour, or other illnesses, individuals often face long-lasting or lifelong physical and personal challenges.

But Australian researcher Associate Professor Jeremy Crook is working to change this with next generation tissue building and regenerative medicine for neural repair. Jeremy was recently appointed as one of two inaugural MedTech Actuator Menzies Fellows to help take him and his team there, faster.

“As a MedTech Actuator Menzies Fellow I will focus on translating our work on electric tissue engineering to a healthcare outcome,” says Jeremy.

“The fellowship is an opportunity for me to learn from leading experts in MedTech commercialisation, as well as connect with others in the broader ecosystem. By increasing our commercialisation focus now, I hope to accelerate translation of our world-first wireless electroceutical for neural repair.”

The fellowship complements recently awarded funding from the National Health and Medical Research Council to further develop their technology through pre-clinical testing. The work was also recently awarded the inaugural Research Australia 2019 Health and Medical Research Frontiers Research Award.

“Our work has now progressed to an advanced propriety electrostimulation platform for 3D bench-top tissue building and within-body tissue repair,” says Jeremy.

Jeremy is Chief Investigator for the Synthetic Biosystems theme of the ARC Centre of Excellence for Electromaterials Science, and Principal Fellow at the University of Wollongong – home of the Centre and the Intelligent Polymer Research Institute.

Jeremy and his team’s research integrates technology, stem cells, biomaterials, 3D bioprinting and bioelectrics, and strengthens Australia’s position as a global leader in tissue engineering and electroceuticals for advanced research and medicine.

The MedTech Actuator Menzies Fellowships are valued at $70,000 each and will provide Jeremy with tailored mentoring from commercialisation experts, a $20,000 stipend and access to the MedTech Actuator™ – Asia Pacific’s MedTech catalyst.

Jeremy says that he is excited to learn what it takes to bring a medical technology innovation to market.

“The fellowship will be important for achieving my aspirations to translate what began as an idea conceived by myself and team member Dr Eva Tomaskovic-Crook into a clinically useful medical technology,” says Jeremy.

The MedTech Actuator Menzies Fellowship is a partnership between the Menzies Foundation and the MedTech Actuator, supported by the Menzies Foundation as part of their Entrepreneurship in Science mission.

Sign up to our newsletter below and connect with us on Twitter and LinkedIn to follow Jeremy’s journey – and stay in the loop on how to be a part of the 2022 MedTech Actuator Menzies Fellowship.

Supporting people with low vision to live their life the way they choose

MedTech Actuator Menzies Fellow and CueSleeve co-founder Dr Chris McCarthy is working to make it easier for people living with low vision and neurocognitive disorders to do what they want and love to do.

It can be challenging for people living with low vision to identify and move towards objects in their everyday life – whether at home or getting around on public transport, dining and more. For people living with neurocognitive disorders such as traumatic brain injury, movement to interact with their world can also be a significant challenge.

“Through this technology we aim to provide a low-cost assistive aid for people with low vision, and an accessible therapeutic aid for rehabilitation of hand-eye coordination in people living with low vision and neurocognitive disorders,” says Chris.

“The MedTech Actuator Menzies Fellowship will provide both the financial support and mentorship we need to develop and commercialise CueSleeve.”

The first prototype is the result of years of hard work from Chris’ PhD student and co-founder Deepa Prabhu, and the CueSleeve team including Mehedi Hasan, Dr Clare MacMahon (La Trobe University) and Dr Lisa Wise.

“CueSleeve is a wearable and flexible sleeve that computes and then delivers vibration-based cues to the user’s forearm skin, guiding them towards objects that they are interested in looking at more closely, touching or picking up,” says Chris.

CueSleeve detects and tracks the objects with sensors embedded within the sleeve and a head-mounted camera using advanced computer vision.

A Senior Lecturer in Computer Science at Swinburne University of Technology, Chris has worked at the forefront of prosthetic vision with Bionic Vision Australia and in developing a robotic aid for paediatric rehabilitation – now deployed at The Royal Children’s Hospital, Melbourne.

The MedTech Actuator Menzies Fellowships are valued at $70,000 each and will provide Chris with tailored mentoring from commercialisation experts, a $20,000 stipend and access to the MedTech Actuator™ – Asia Pacific’s MedTech, BioTech and HealthTech accelerator.

“I am excited to learn about entrepreneurship and business from the experts, and to bring this project, already years in the making, out of the lab and into the hands of people we believe it can truly benefit.”

The MedTech Actuator Menzies Fellowship is a partnership between the Menzies Foundation and the MedTech Actuator, supported by the Menzies Foundation as part of their Entrepreneurship in Science mission.

Sign up to our newsletter below and connect with us on Twitter and LinkedIn to follow Chris’ journey – and stay in the loop on how to be a part of the 2022 MedTech Actuator Menzies Fellowship.